Assessing immune and inflammatory markers in blood to predict glioma prognosis
Preoperative Immune and Inflammatory Indices in Peripheral Blood Predict Prognosis of Glioma and Correlate With Grades and Subtypes: A Prospective Multi-Institutional Study
This study is testing if certain immune and inflammation markers in the blood can help predict how well people with glioma will do after their diagnosis.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1282 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Sun Yat-sen University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 3 sites (Beijing, Beijing and 2 other locations) |
| Trial ID | NCT05635435 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the relationship between immune and inflammatory indices in peripheral blood and the prognosis of glioma, utilizing a large cohort of 1,282 patients from various regions in China. Key indices such as immunoglobulin kappa light chain, TNF, and CD4+ Helper T lymphocyte percentages are analyzed to determine their correlation with glioma grades and subtypes. The study aims to enhance diagnostic and prognostic processes for glioma by leveraging preoperative inflammatory status for timely interventions that could improve patient outcomes.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 years with histologically verified primary malignant glioma and available immune data from their first hospitalization.
Not a fit: Patients with current infectious diseases, other cancers, or those who have undergone prior cancer-specific treatments may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic and prognostic capabilities for glioma patients, potentially enhancing treatment strategies.
How similar studies have performed: While similar studies have explored immune markers in cancer prognosis, this specific approach in glioma is relatively novel and untested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * glioma grading and classification histologically verified in a resection or biopsy specimen according to 2016 WHO criteria; * age \> 18 years; * primary malignant glioma; * the duration of follow-up \> 3 months; * available data of lymphocyte subsets, cytokines, immune proteins and immune complements measured at the patient's first hospitalization. Exculsion Criteria: * current infectious disease, hyperpyrexia, hematological disease, diabetes mellitus, serious heart disease, hypertension, metabolic syndrome, severe renal or hepatic dysfunction, other cancer, autoimmune disease, inflammatory disease, or medication usage related to an inflammatory condition; * prior cancer-specific pretreatment, such as chemotherapy or radiotherapy;
Where this trial is running
Beijing, Beijing and 2 other locations
- Xuanwu Hospital, Capital Medical University — Beijing, Beijing, China (Recruiting)
- Sun Yat-sen University Cancer Center — Guanzhou, Guangdong, China (Completed)
- The First Bethune Hospital of Jilin University — Chang chun, Jilin, China (Recruiting)
Study contacts
- Study coordinator: Sheng Zhong, M.D.
- Email: zhongsheng@sysucc.org.cn
- Phone: 18743037749
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.